The effectiveness of inhaled Cannabis flower for the treatment of agitation/irritability, anxiety, and common stress

Table 4 Session product characteristics’ effects on symptom relief when using inhaled, dried Cannabis flower and treating cannabinoid measurements as continuous variables

	Overall Sample	Agitation/irritability	Anxiety	Stress
	(1)	(2)	(3)	(4)
THC (%/dry wt.)	− 0.020*** (0.006)	0.006 (0.018)	− 0.024** (0.008)	− 0.021* (0.009)
CBD (%/dry wt.)	− 0.002 (0.009)	0.012 (0.015)	− 0.001 (0.010)	− 0.001 (0.012)
C. indica	− 0.014 (0.104)	− 0.209 (0.215)	0.033 (0.133)	0.018 (0.169)
C. sativa	0.215 (0.111)	0.162 (0.209)	0.222 (0.127)	0.250 (0.166)
Pipe	0.093 (0.256)	0.499 (0.653)	− 0.385 (0.213)	0.498 (0.409)
Vape	0.135 (0.274)	0.708 (0.664)	− 0.222 (0.268)	0.492 (0.406)
Session length (min)	− 0.007*** (0.001)	− 0.005* (0.002)	− 0.007*** (0.001)	− 0.008*** (0.001)
Baseline symptom intensity	− 0.662*** (0.040)	− 0.694*** (0.071)	− 0.608*** (0.069)	− 0.669*** (0.052)
Constant	0.281 (0.296)	− 0.801 (0.744)	0.639 (0.379)	− 0.058 (0.437)
Number of sessions	2306	422	998	886
Number of users	670	206	441	360

Each column represents a separate regression. The outcome is the difference between the lowest reported symptom level within 4 h of initiating the session and the starting symptom level. The first column reports results for the whole sample, while columns 2 to 4 distinguish between specific distress-related symptoms reported. C. indica and C. sativa are relative to hybrid strains, and pipe and vape are relative to joint. All regressions are estimated using a fixed effects model and control for session length and baseline symptom intensity. Standard errors, clustered at the individual user level, are shown in parentheses
***p < 0.001, **p < 0.01, *p < 0.05

ISSN: 2522-5782